Glycomine Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 20

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 17

Glycomine General Information

Description

Developer of orphan drugs designed to treat rare disorders of metabolism and protein misfolding. The company's drugs combine replacement therapies such as substrates, enzymes, and proteins with intracellular delivery vehicles consisting of bio-nano materials and ligands that target the molecules to the cell interior of clinically relevant organs, enabling physicians to efficiently treat their patients.

Contact Information

Website
www.glycomine.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • MBC BioLabs
  • 733 Industrial Road
  • San Carlos, CA 94070
  • United States
+1 (650) 000-0000
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Nanotechnology, Life Sciences
Corporate Office
  • MBC BioLabs
  • 733 Industrial Road
  • San Carlos, CA 94070
  • United States
+1 (650) 000-0000

Glycomine Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Glycomine Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 13-Jun-2023 000.00 Completed Clinical Trials - Phase 1
4. Later Stage VC (Series B) 11-Jun-2021 0000 000.00 00000 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series A) 16-Nov-2016 0000 000.00 000.00 Completed Clinical Trials - Phase 1
2. Accelerator/Incubator 01-Jan-2016 $630K $630K Completed Clinical Trials - Phase 1
1. Accelerator/Incubator Completed Startup
To view Glycomine’s complete valuation and funding history, request access »

Glycomine Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B-2 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B-1 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 1,337,056 $0.000100 $3.8 $3.8 1x $3.8 1.92%
To view Glycomine’s complete cap table history, request access »

Glycomine Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of orphan drugs designed to treat rare disorders of metabolism and protein misfolding. The company's drugs com
Drug Discovery
San Carlos, CA
20 As of 2022
000.00
0000000000 0 000.00

000000

t enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliqui
0000 000000000
White Bear Lake, MN
0 As of 0000
00.00
000000&0 00.00

000000

didunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud e
0000000000000
Waltham, MA
000 As of 0000
00000
00000 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Glycomine Competitors (54)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
MnPharm Formerly VC-backed White Bear Lake, MN 0 00.00 000000&0 00.00
Visterra Formerly VC-backed Waltham, MA 000 00000 000000&0 00000
Gadeta Formerly VC-backed Utrecht, Netherlands 00 00.000 000000&0 00.000
Carisma Therapeutics Formerly VC-backed Philadelphia, PA 00 00000 000000000 00000
MiNA Therapeutics Venture Capital-Backed London, United Kingdom 00 00000 0000 00000
You’re viewing 5 of 54 competitors. Get the full list »

Glycomine Patents

  • 18

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 8

    Granted

  • 7

    Pending

  • 000

    Expiring in next 12 mo

Glycomine Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220184107-A1 Liposomal formulations, and methods of using and preparing thereof Pending 29-Mar-2019 00000000000 0
EP-3946365-A1 Liposomal formulations, and methods of using and preparing thereof Pending 29-Mar-2019 00000000000
CA-3134828-A1 Liposomal formulations, and methods of using and preparing thereof Pending 29-Mar-2019 00000000000
AU-2020252005-A1 Liposomal formulations, and methods of using and preparing thereof Pending 29-Mar-2019 00000000000
EP-3946365-A4 Liposomal formulations, and methods of using and preparing thereof Pending 29-Mar-2019 A61K31/7004
To view Glycomine’s complete patent history, request access »

Glycomine Executive Team (9)

Name Title Board Seat
Geoffrey Hird Ph.D Chief Technology Officer
Hicham Alaoui Ph.D Chief Scientific Officer
Peter McWilliams Ph.D Chief Business Officer & Board Member
Rose Marino MD Chief Medical Officer
Steven Axon Chief Executive Officer & Board Member
You’re viewing 5 of 9 executive team members. Get the full list »

Glycomine Board Members (12)

Name Representing Role Since
Bali Muralidhar Ph.D Abingworth Board Member 000 0000
Christopher Starr Ph.D Self Chairman of the Board 000 0000
Jacqueline Grant Ph.D Abingworth Board Member 000 0000
Jason Hafler Ph.D Sanofi Ventures Board Member 000 0000
Jim Trenkle Ph.D Sanofi Ventures Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Glycomine Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Glycomine Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
Abingworth Venture Capital Minority 000 0000 000000 0
Asahi Kasei Pharma Venture Capital Corporate Venture Capital Minority 000 0000 000000 0
Mesa Verde Venture Partners Venture Capital Minority 000 0000 000000 0
Mission Bay Capital Venture Capital Minority 000 0000 000000 0
Mission BioCapital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 17 investors. Get the full list »

Ready to get started?

Request a free trial

Glycomine FAQs

  • When was Glycomine founded?

    Glycomine was founded in 2014.

  • Who is the founder of Glycomine?

    Agnes Rafalko Ph.D is the founder of Glycomine.

  • Who is the CEO of Glycomine?

    Steven Axon is the CEO of Glycomine.

  • Where is Glycomine headquartered?

    Glycomine is headquartered in San Carlos, CA.

  • What is the size of Glycomine?

    Glycomine has 20 total employees.

  • What industry is Glycomine in?

    Glycomine’s primary industry is Drug Discovery.

  • Is Glycomine a private or public company?

    Glycomine is a Private company.

  • What is Glycomine’s current revenue?

    The current revenue for Glycomine is 00000.

  • How much funding has Glycomine raised over time?

    Glycomine has raised $80.6M.

  • Who are Glycomine’s investors?

    Abingworth, Asahi Kasei Pharma Venture Capital, Mesa Verde Venture Partners, Mission Bay Capital, and Mission BioCapital are 5 of 17 investors who have invested in Glycomine.

  • Who are Glycomine’s competitors?

    MnPharm, Visterra, Gadeta, Carisma Therapeutics, and MiNA Therapeutics are some of the 54 competitors of Glycomine.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »